Concerns over Drug Resistance in Gram-Negative Infections Has Led to the Uptake of Drugs Typically Used for Later Lines of Therapy, Including Meropenem, Merck`s Primaxin and Invanz, Janssen`s Doribax, Pfizer`s Tygacil and Co